<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04366869</url>
  </required_header>
  <id_info>
    <org_study_id>OctoberUMSA</org_study_id>
    <nct_id>NCT04366869</nct_id>
  </id_info>
  <brief_title>Which is More Effective in Management of Bruxism: Botox or Occlusal Splints</brief_title>
  <official_title>Which is More Effective in Management of Bruxism for Implant Overdenture Patients: Botox or Occlusal Splints - A One Year Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>October University for Modern Sciences and Arts</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>October University for Modern Sciences and Arts</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the efficacy of Botulinum toxin (Botox) and traditional
      occlusal splints for the management of bruxism in edentulous patients rehabilitated with MIOD
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      42 edentulous patients having implant retained mandibular overdenture suffering from bruxism
      with clinical manifestation, will be randomly divided into three groups, group 1 control
      group (traditional approach of removing denture at night) ,group 2 will be managed by
      occlusal splints whereas group 3 will be managed with botulinum toxin injection (Botox). New
      maxillary dentures and mandibular over dentures will be constructed for both groups. Muscle
      activity will be measured at time of denture insertion (T0), 3(T3) 6(T6), 9(T9) and 12(T12)
      month of treatment. Patients satisfaction will be evaluated at the time of denture insertion
      (T0), 6(T6), and 12(T12) month of treatment using TMD/ NS numeric scales 10 cm questionnaire
      which include: headache, face pain, face tension, limitation of mouth opening and complaints
      during mastication.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 7, 2019</start_date>
  <completion_date type="Anticipated">August 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 7, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Patient satisfaction: questionnaire</measure>
    <time_frame>12months</time_frame>
    <description>Patients satisfaction was evaluated using TMD/ NS numeric scales 10 cm questionnaire which included: headache, face pain, face tension, limitation of mouth opening and complaints during mastication with scores from 1 to 10 whereas 1 means least pain and 10 means highest pain.it was assessed at baseline (T0), then after 3months(T3) then after 6months from baseline(T6), then after 9months from baseline(T9) and finally after 12 months from baseline (T12). which means every 3 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Electromyography</measure>
    <time_frame>12 months</time_frame>
    <description>measuring muscle activity for massetter and temporalis muscle at baseline,3,6,9,12 months</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Bruxism</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>traditional approach of removing denture at night</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>occlusal splint</description>
  </arm_group>
  <arm_group>
    <arm_group_label>intervention 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Botox</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>overdenture</intervention_name>
    <description>removal of overdenture at night</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>occlusal splint</intervention_name>
    <description>occlusal splint on overdenture</description>
    <arm_group_label>intervention 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox</intervention_name>
    <description>Botox injection i masseter in temporalis</description>
    <arm_group_label>intervention 2</arm_group_label>
    <other_name>Bolitinum Toxins</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients diagnosed with bruxism

          -  patients had mandibular implant retained overdentures within the previous 3 years

          -  cooperative patients

          -  physically and psychologically able patients to tolerate the procedure

        Exclusion Criteria:

          -  patients taking muscle relaxants

          -  patients without neuromuscular control

          -  poor oral hygiene
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dina Elawady, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MSA</name>
      <address>
        <city>Giza</city>
        <zip>311</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 21, 2020</study_first_submitted>
  <study_first_submitted_qc>April 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 29, 2020</study_first_posted>
  <last_update_submitted>April 28, 2020</last_update_submitted>
  <last_update_submitted_qc>April 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>October University for Modern Sciences and Arts</investigator_affiliation>
    <investigator_full_name>Dina ElAwady</investigator_full_name>
    <investigator_title>lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bruxism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

